Reported Earlier, FDA Approves Geron's RYTELO (imetelstat), A Novel Telomerase Inhibitor, For Treating Lower-Risk MDS In Adults With Transfusion-Dependent Anemia

Author: Benzinga Newsdesk | June 07, 2024 01:53am

• Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast (RS) status
• Durable and sustained red blood cell transfusion independence, increases in hemoglobin levels and reduction in transfusion burden observed across key LR-MDS subgroups in the IMerge Phase 3 clinical trial; the most common Grade 3/4 adverse reactions were thrombocytopenia and neutropenia, which were generally manageable and short-lived
• Lower-risk MDS is a progressive blood cancer with high unmet need, where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and decreased quality of life
• Conference call with Geron management scheduled at 8am ET on Friday, June 7, 2024

Posted In: GERN